Clinical Trial

Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia

Study acronym: ASCEND-VT
Recruiting
View on ClinicalTrials.gov →
Summary
ASCEND is a randomized controlled open-label pilot study evaluating the safety and effectiveness of pulsed field ablation (PFA) with the novel FARAPOINT catheter compared to the standard radiofrequency (RFA) ablation with ThermoCool ST/FlexAbility SE/ThermoCool ST SF/TactiFlex SE of ventricular tachycardia (VT) in the patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator (ICD). The study hypothesis is that the PFA ablation is more efficient compared to the RFA technique but retains a comparable safety profile.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-17; most recent amendment 2025-08-14.
Status change: Not Yet Recruiting → Recruiting 2025-06-18
Trial Details
NCT Number NCT06891456
Lead Sponsor Pasquale Santangeli
Collaborators: Boston Scientific Corporation
Conditions Ventricular Tachycardia, Ischemic Heart Disease, Sustained VT
Enrollment 40 participants
Start Date 2025-06-16
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-19